Advertisement

Topics

Latest "Galectin Therapeutics" News Stories

13:21 EDT 26th June 2016 | BioPortfolio

Here are the most relevant search results for "Galectin Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Galectin Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Galectin Therapeutics for you to read. Along with our medical data and news we also list Galectin Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Galectin Therapeutics Companies for you to search.

Showing "Galectin Therapeutics" News Articles 1–25 of 6,000+

Extremely Relevant

Enrollment in NASH-FX trial for advanced fibrosis, NASH complete

Galectin Therapeutics Inc. announced enrollment is complete for its phase 2 NASH-FX trial investigating GR-MD-02, a complex carbohydrate drug that targets galectin-3, for the treatment of nonalcoholic steatohepatitis and advanced fibrosis.The study, which will be led by Stephen A. Harrison, MD, FACP, FAASLD, professor of medicine at the Uniformed Services University of the Health Sciences, San Ant...


Relevant

Galectin completes enrollment for phase 2 trial of GR-MD-02 in fibrosis patients

Galectin Therapeutics has completed enrollment in its phase 2 clinical trial of GR-MD-02 in patients with non-alcoholic steatohepatitis (NASH) with advanced fibrosis (stage 3).

Galectin appoints Dr. Marc Rubin as chairman

Galectin Therapeutics (NASDAQ:GALT) has announced the election of Dr. Marc Rubin as chairman, succeeding James Czirr, who helped found the company in 2000. Mr. Czirr will continue as a director. Dr. Rubin is a leading bioscience industry executive with more than 25 years of senior management and board experience in the development and commercialization of […]


Galectin-3 And Cardiac Troponins Reference Values Determined

Galectin-3 is a unique member of chimera type galectins and is involved in a large number of disease processes and...

Galectin Therapeutics' (GALT) CEO Peter Traber on Q4 2015 Results - Earnings Call Transcript

BRIEF-Galectin Therapeutics completes enrollment in mid stage trial for NASH drug

* Completion of enrollment in phase 2 clinical trial with GR-MD-02 in patients with NASH with advanced fibrosis

Osteoarthritis: Galectin-1 damages cartilage via inflammation

Galectin-3 inhibition prevents adipose tissue remodelling in obesity

Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling

BG Medicine Withdraws 510(k) Premarket Notification for Proposed Additional Indication for the BGM Galectin-3® Test

WALTHAM, Mass., Dec. 23, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (OTCQB:BGMD)  today announced that it has submitted to the FDA a notice of withdrawal of its 510(k) premarket notification filing with the US Food and Drug Administration (“FDA”) that was submitted in order to obtain regulatory clearance to market its BGM Galectin-3® Test for a potential new indication for use as an aid...

Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo

As big pharma moves in, biotech Galectin looks to stake claim to NASH market

NASH, a fatty liver disease, has grown in prevalence, with some saying it will replace hepatitis C as the main cause of liver transplantation by 2020. 

Anti-galectin-3 (LGALS3) mAb-based PET imaging agent to diagnose thyroid cancer

A mAb-based PET imaging agent targeting

Galectins in tumour immunity

Dr Gabriel Rabinovich meets with ecancertv at AACR 2016 to discuss galectins. In particular, he has worked with Galectin 1 which, when secreted by tumour cells, kills t cells and promotes non-immunogenic tumourous dendritic cell growth. Beyond immune...

BIND Therapeutics collaborates with Affilogic

BIND Therapeutics, a company developing targeted and programmable therapeutics called ACCURINS, has signed…

Placon Therapeutics launches, BTP-114 IND accepted by FDA

Placon Therapeutics, a biotechnology company developing next-generation platinum-based cancer therapies, has launched as an independent company and provided an update on its lead product candidate, BTP-114, for which the FDA has accepted an Investigational New Drug (IND) application to begin clinical evaluation in cancer patients. Placon was spun out from Blend Therapeutics (now Tarveda Therapeuti...

Bicycle Therapeutics establishes U.S. operations

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptides (Bicycles) platform, has established U.S. operations with headquarters in Cambridge, Massachusetts and named Rosamond Deegan, MBA, as president and chief business officer. In this newly created role, Deegan will be responsible for leading Bicycle Therapeutics’ business ...

Living Therapeutics

An MIT spinout, Synlogic, is aiming to create a new class of medicines, by re-programming bacteria found in the gut as “living therapeutics.”Read more about Living Therapeutics Comments

Tarveda spins platinum-based drug assets out into newco Placon Therapeutics

Tarveda Therapeutics Inc. (formerly Blend Therapeutics) spun out its development-stage platinum-based cancer assets into a new independent entity named Placon Therapeutics.

Wilson Therapeutics AB: Change in Number of Shares in Wilson Therapeutics

Regulatory News: Wilson Therapeutics (STO:WTX) The number of shares and votes in Wilson Therapeutics AB (publ) has changed as a result of the new issue of shares that was made in connection with t...

Intensity Therapeutics Inc.

Intensity Therapeutics Inc.'s DfuseRx platform combines known, potent chemotherapeutics with cell-penetration enhancing compounds. The resulting therapeutics are designed to kill tumor cells in masses and then prime the immune system to seek out metastases.

AstraZeneca to collaborate with Moderna Therapeutics to develop mRNA therapeutics

Anglo-Swedish pharma company AstraZeneca will join forces with US biotech firm Moderna Therapeutics to…

#jobs #lifescience PsiOxus Therapeutics: Analytical Development Scientist – Oxfordshire

// Attractive remuneration package: PsiOxus Therapeutics: PsiOxus Therapeutics Ltd is an Oxford based development stage biotechnology company developing novel therapeutics… Oxfordshire from Job Search RSS http://ift.tt/22q9aVt Cet article #jobs #lifescience PsiOxus Therapeutics: Analytical Development Scientist – Oxfordshire est apparu en premier sur Biotech 365.

Wilson Therapeutics AB: Wilson Therapeutics Announces That the Ongoing Phase II Study Has Been Fully Enrolled

STOCKHOLM–(BUSINESS WIRE)–Regulatory News: Wilson Therapeutics (STO:WTX) Wilson Therapeutics AB (publ), announces that the company’s ongoing Phase II clinical trial evaluating the safety and efficacy of Decuprate® (bis-choline tetrathiomolybdate; WTX101) in Wilson Disease patients has been fully enrolled. WTX101-201 is a … Continue reading → Cet article Wilson Th...

Bayer, CRISPR Therapeutics AG to Collaborate on Genetic Disease Research

Bayer and CRISPR Therapeutics have entered into an agreement to create a joint venture (JV) to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering ex...


Quick Search
Advertisement
 

News Quicklinks